Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07486518 | A Multicentre Observational Cross-Sectional Study of The Gastric Precancerous Epithelial Pathway Using High-Definition Endoscopy And Histopathology In India(IND-PREP) | recruiting | — | 4,000 | Asian Institute of Gastroenterology, IndiaOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER |
| 1 |
| Aug 31, 2026 |
| clinicaltrials |
| NCT00433511 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | active not recruiting | Phase 3 | 4,994 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT00923026 | Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies | enrolling by invitation | — | 1,150 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01081262 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | active not recruiting | Phase 3 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | active not recruiting | Phase 3 | 5,018 | National Cancer Institute (NCI)NIH | 10 | Aug 28, 2026 | clinicaltrials |
| NCT02142803 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02152995 | Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | active not recruiting | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 / Phase 3 | 444 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03055013 | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | active not recruiting | Phase 3 | 819 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT03366155 | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03371719 | Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial | active not recruiting | Phase 2 | 298 | NRG OncologyOTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03595124 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | active not recruiting | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT04090710 | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer(CYTOSHRINK) | completed | Phase 2 | 66 | Ontario Clinical Oncology Group (OCOG)OTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT04427293 | Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 | 12 | University of Illinois at ChicagoOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04677816 | Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients | recruiting | Phase 2 | 50 | Wake Forest University Health SciencesOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06068985 | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade(CHERRY-PICK) | active not recruiting | Phase 2 | 63 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07029399 | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 361 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07669727 | A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.(ADVANCE-MCD) | not yet recruiting | — | 140 | Boston Scientific CorporationINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07780357 | HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B | not yet recruiting | — | 2,000 | Beijing Friendship HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03674073 | A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma | completed | Phase 1 | 24 | Chinese PLA General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04669860 | Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma | suspended | — | 90 | University of MiamiOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06234488 | Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study | completed | — | 125 | Medical College of WisconsinOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06414733 | HER-2 B Cell Peptide Vaccine | recruiting | Phase 1 | 42 | Pravin T.P KaumayaOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06698458 | Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer | recruiting | N/A | 50 | Alpha Tau Medical LTD.INDUSTRY | 3 | Aug 27, 2026 | clinicaltrials |
| NCT06949410 | HER2 Vaccine for Locally Advanced Breast Cancer | recruiting | Phase 1 | 36 | Pravin T.P KaumayaOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | recruiting | Phase 1 | 200 | Sutro Biopharma, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07544589 | A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers | recruiting | Phase 1 | 66 | Dispatch BiotherapeuticsINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07630961 | Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07640295 | Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations | recruiting | Phase 1 / Phase 2 | 80 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07658196 | TLR9 Immunotherapy for Peritoneal Carcinomatosis(TIPC) | recruiting | Phase 1 | 24 | Brown UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07753824 | A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) | not yet recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07791329 | Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer(GastroPET) | completed | Phase 2 | 144 | Masaryk Memorial Cancer InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT00334815 | Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02993068 | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) | suspended | N/A | 5,200 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03204123 | PSMA PET Imaging of Recurrent Prostate Cancer | active not recruiting | Phase 2 | 1,171 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | terminated | Phase 2 | 18 | University of WashingtonOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | completed | Phase 3 | 738 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT03644186 | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)(TOUCH) | completed | Phase 2 | 147 | ETOP IBCSG Partners FoundationNETWORK | 4 | Aug 26, 2026 | clinicaltrials |
| NCT04034927 | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | active not recruiting | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04157127 | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma(DECIST) | recruiting | Phase 1 | 18 | Diakonos Oncology CorporationINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05063565 | TheraSphere With Durvalumab and Tremelimumab for HCC(ROWAN) | active not recruiting | Phase 2 | 100 | Boston Scientific CorporationINDUSTRY | 5 | Aug 26, 2026 | clinicaltrials |
| NCT05281471 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | recruiting | Phase 3 | 186 | Genelux CorporationINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06123988 | Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer(FastER) | recruiting | N/A | 260 | University of MiamiOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06187961 | HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma(CCGLC-011) | recruiting | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 31, 2026source: clinicaltrials